Published in J Virol on September 01, 2006
Cross-species virus transmission and the emergence of new epidemic diseases. Microbiol Mol Biol Rev (2008) 4.46
HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology (2008) 3.72
Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol (2009) 2.95
Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol (2007) 2.95
APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog (2008) 2.60
Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J Virol (2006) 2.50
Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res (2007) 2.49
Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J Virol (2007) 2.47
Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med (2010) 2.43
Host restriction factors blocking retroviral replication. Annu Rev Genet (2008) 2.41
APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci (2009) 2.40
The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J Virol (2008) 2.21
Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation. J Virol (2007) 2.17
Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J Virol (2007) 2.03
7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G. J Virol (2007) 1.91
RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog (2009) 1.84
APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection. J Exp Med (2006) 1.82
All APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition. Nucleic Acids Res (2007) 1.79
The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA. J Virol (2007) 1.74
New developments in the induction and antiviral effectors of type I interferon. Curr Opin Immunol (2010) 1.67
Deaminase-independent inhibition of parvoviruses by the APOBEC3A cytidine deaminase. PLoS Pathog (2009) 1.65
Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. J Virol (2008) 1.59
Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly. J Virol (2008) 1.57
Differential inhibition of long interspersed element 1 by APOBEC3 does not correlate with high-molecular-mass-complex formation or P-body association. J Virol (2007) 1.53
Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. J Virol (2007) 1.53
Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity. Retrovirology (2007) 1.52
Enhanced replication and pathogenesis of Moloney murine leukemia virus in mice defective in the murine APOBEC3 gene. Virology (2009) 1.51
Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J Virol (2007) 1.51
Hypermutation of an ancient human retrovirus by APOBEC3G. J Virol (2008) 1.50
Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent. Virology (2009) 1.50
Interactions of murine APOBEC3 and human APOBEC3G with murine leukemia viruses. J Virol (2008) 1.50
Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J Virol (2007) 1.47
The APOBEC3 family of retroelement restriction factors. Curr Top Microbiol Immunol (2013) 1.46
Species-specific restriction of apobec3-mediated hypermutation. J Virol (2007) 1.46
Evolutionarily conserved and non-conserved retrovirus restriction activities of artiodactyl APOBEC3F proteins. Nucleic Acids Res (2006) 1.46
APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms. J Virol (2010) 1.40
HIV-1 accessory proteins VPR and Vif modulate antiviral response by targeting IRF-3 for degradation. Virology (2007) 1.40
Genetic editing of HBV DNA by monodomain human APOBEC3 cytidine deaminases and the recombinant nature of APOBEC3G. PLoS One (2009) 1.39
Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. J Mol Biol (2013) 1.39
Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1. FASEB J (2008) 1.39
A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity. J Virol (2009) 1.38
Comparison of cellular ribonucleoprotein complexes associated with the APOBEC3F and APOBEC3G antiviral proteins. J Virol (2008) 1.37
Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. J Virol (2008) 1.37
Conserved footprints of APOBEC3G on Hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences. J Virol (2008) 1.36
Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3). Retrovirology (2008) 1.36
A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. J Virol (2009) 1.36
The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains. Virology (2007) 1.33
Addition of deoxynucleosides enhances human immunodeficiency virus type 1 integration and 2LTR formation in resting CD4+ T cells. J Virol (2007) 1.31
HIV-1 reverse transcription. Cold Spring Harb Perspect Med (2012) 1.29
Apobec 3G efficiently reduces infectivity of the human exogenous gammaretrovirus XMRV. PLoS One (2010) 1.28
APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA. Retrovirology (2009) 1.27
Two regions within the amino-terminal half of APOBEC3G cooperate to determine cytoplasmic localization. J Virol (2008) 1.24
APOBEC3G subunits self-associate via the C-terminal deaminase domain. J Biol Chem (2008) 1.24
Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins. PLoS One (2008) 1.23
Biochemical differentiation of APOBEC3F and APOBEC3G proteins associated with HIV-1 life cycle. J Biol Chem (2006) 1.19
T cells contain an RNase-insensitive inhibitor of APOBEC3G deaminase activity. PLoS Pathog (2007) 1.19
Mutation rates and intrinsic fidelity of retroviral reverse transcriptases. Viruses (2009) 1.19
Severe restriction of xenotropic murine leukemia virus-related virus replication and spread in cultured human peripheral blood mononuclear cells. J Virol (2011) 1.18
The AKV murine leukemia virus is restricted and hypermutated by mouse APOBEC3. J Virol (2009) 1.17
Human APOBEC3G can restrict retroviral infection in avian cells and acts independently of both UNG and SMUG1. J Virol (2008) 1.17
Stably expressed APOBEC3F has negligible antiviral activity. J Virol (2010) 1.15
Biochemical and biological studies of mouse APOBEC3. J Virol (2014) 1.14
The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G. Retrovirology (2007) 1.14
APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic virus type 1. J Virol (2012) 1.14
Interaction of Vpx and apolipoprotein B mRNA-editing catalytic polypeptide 3 family member A (APOBEC3A) correlates with efficient lentivirus infection of monocytes. J Biol Chem (2010) 1.12
Differential expression of HIV-1 interfering factors in monocyte-derived macrophages stimulated with polarizing cytokines or interferons. Sci Rep (2012) 1.12
Characterization of the interaction of full-length HIV-1 Vif protein with its key regulator CBFβ and CRL5 E3 ubiquitin ligase components. PLoS One (2012) 1.12
Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function. J Virol (2010) 1.12
Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors. Microbiol Mol Biol Rev (2009) 1.12
The role of cytidine deaminases on innate immune responses against human viral infections. Biomed Res Int (2013) 1.11
Vif is a RNA chaperone that could temporally regulate RNA dimerization and the early steps of HIV-1 reverse transcription. Nucleic Acids Res (2007) 1.07
CD63 is not required for production of infectious human immunodeficiency virus type 1 in human macrophages. J Virol (2008) 1.07
APOBEC3D and APOBEC3F potently promote HIV-1 diversification and evolution in humanized mouse model. PLoS Pathog (2014) 1.07
Vif substitution enables persistent infection of pig-tailed macaques by human immunodeficiency virus type 1. J Virol (2011) 1.05
Induction of APOBEC3 in vivo causes increased restriction of retrovirus infection. J Virol (2009) 1.05
Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity. Proteins (2007) 1.04
APOBEC3G restricts early HIV-1 replication in the cytoplasm of target cells. Virology (2008) 1.04
The restriction of zoonotic PERV transmission by human APOBEC3G. PLoS One (2007) 1.04
HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors. Mol Aspects Med (2010) 1.03
The cellular antiviral protein APOBEC3G interacts with HIV-1 reverse transcriptase and inhibits its function during viral replication. J Virol (2012) 1.03
Inhibition of alpharetrovirus replication by a range of human APOBEC3 proteins. J Virol (2007) 1.03
The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals. AIDS Res Hum Retroviruses (2008) 1.02
APOBEC3G: an intracellular centurion. Philos Trans R Soc Lond B Biol Sci (2009) 1.02
Dissociation of in vitro DNA deamination activity and physiological functions of AID mutants. Proc Natl Acad Sci U S A (2008) 1.02
Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection. PLoS One (2008) 1.01
Structural determinants of human APOBEC3A enzymatic and nucleic acid binding properties. Nucleic Acids Res (2013) 1.01
Suppression of APOBEC3-mediated restriction of HIV-1 by Vif. Front Microbiol (2014) 1.00
Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded Vif. J Virol (2010) 1.00
Productive replication of Vif-chimeric HIV-1 in feline cells. J Virol (2010) 0.99
Distinct viral determinants for the packaging of human cytidine deaminases APOBEC3G and APOBEC3C. Virology (2008) 0.99
APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication. PLoS Pathog (2008) 0.99
Retroelements versus APOBEC3 family members: No great escape from the magnificent seven. Front Microbiol (2012) 0.99
Restriction of equine infectious anemia virus by equine APOBEC3 cytidine deaminases. J Virol (2009) 0.98
APOBEC3 inhibition of mouse mammary tumor virus infection: the role of cytidine deamination versus inhibition of reverse transcription. J Virol (2013) 0.97
Infection barriers to successful xenotransplantation focusing on porcine endogenous retroviruses. Clin Microbiol Rev (2012) 0.97
Conserved and non-conserved features of HIV-1 and SIVagm Vif mediated suppression of APOBEC3 cytidine deaminases. Cell Microbiol (2008) 0.97
Vif of feline immunodeficiency virus from domestic cats protects against APOBEC3 restriction factors from many felids. J Virol (2010) 0.97
APOBEC3G: a double agent in defense. Trends Biochem Sci (2011) 0.96
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature (2002) 21.53
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother (2002) 13.91
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature (2003) 13.24
DNA deamination mediates innate immunity to retroviral infection. Cell (2003) 12.10
Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science (2003) 10.79
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature (2003) 10.76
Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell (2003) 9.48
The protein network of HIV budding. Cell (2003) 7.82
An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics (2002) 7.10
Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol (2004) 6.51
Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol (1993) 6.11
A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J (2004) 5.67
Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol (2004) 5.35
Retracted Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature (2005) 5.28
Inhibition of hepatitis B virus replication by APOBEC3G. Science (2004) 5.15
RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol Cell (2002) 5.14
Selection, recombination, and G----A hypermutation of human immunodeficiency virus type 1 genomes. J Virol (1991) 5.03
Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol (2005) 4.98
APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol (2004) 4.89
Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J Virol (2006) 3.63
APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr Biol (2006) 3.57
APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J Biol Chem (2004) 3.56
Complementary function of the two catalytic domains of APOBEC3G. Virology (2005) 3.45
The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J Virol (1996) 3.22
APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Res (2006) 3.15
Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1. J Virol (1993) 3.12
Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci U S A (2005) 2.68
The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J Biol Chem (2005) 2.62
G-->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol (2005) 2.61
APOBEC-mediated editing of viral RNA. Science (2004) 2.15
Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. J Virol (2005) 2.04
Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G. J Virol (2006) 1.98
Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates. Virology (2006) 1.94
G to A hypermutation of hepatitis B virus. Hepatology (2005) 1.83
APOBEC-mediated interference with hepadnavirus production. Hepatology (2005) 1.82
DNA deamination: not just a trigger for antibody diversification but also a mechanism for defense against retroviruses. Nat Immunol (2003) 1.54
Cytidine deamination and resistance to retroviral infection: towards a structural understanding of the APOBEC proteins. Virology (2005) 1.36
Death and the retrovirus. Trends Mol Med (2003) 1.12
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature (2002) 21.53
DNA deamination mediates innate immunity to retroviral infection. Cell (2003) 12.10
The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med (2003) 9.22
Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol (2004) 6.51
Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol (2005) 4.98
APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J Biol Chem (2006) 3.03
Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol (2009) 2.95
APOBEC-mediated viral restriction: not simply editing? Trends Biochem Sci (2007) 2.80
Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature (2013) 2.79
APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog (2008) 2.60
A sensitive, quantitative assay for human immunodeficiency virus type 1 integration. J Virol (2002) 2.54
Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J Virol (2006) 2.50
Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation. J Virol (2007) 2.17
APOBEC-mediated editing of viral RNA. Science (2004) 2.15
Reassessment of the roles of integrase and the central DNA flap in human immunodeficiency virus type 1 nuclear import. J Virol (2002) 1.91
Guidelines for naming nonprimate APOBEC3 genes and proteins. J Virol (2008) 1.86
RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog (2009) 1.84
APOBEC-mediated interference with hepadnavirus production. Hepatology (2005) 1.82
Retroviral mRNA nuclear export elements regulate protein function and virion assembly. EMBO J (2004) 1.77
Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells. J Virol (2010) 1.69
DNA deamination: not just a trigger for antibody diversification but also a mechanism for defense against retroviruses. Nat Immunol (2003) 1.54
Long HIV type 1 reverse transcripts can accumulate stably within resting CD4+ T cells while short ones are degraded. AIDS Res Hum Retroviruses (2004) 1.51
Hypermutation of an ancient human retrovirus by APOBEC3G. J Virol (2008) 1.50
TRIM5 alpha cytoplasmic bodies are highly dynamic structures. Mol Biol Cell (2007) 1.47
Further investigation of simian immunodeficiency virus Vif function in human cells. J Virol (2004) 1.46
Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions. J Virol (2003) 1.41
Comment on "Inhibition of hepatitis B virus replication by APOBEC3G". Science (2004) 1.41
Comparison of cellular ribonucleoprotein complexes associated with the APOBEC3F and APOBEC3G antiviral proteins. J Virol (2008) 1.37
Cytidine deamination and resistance to retroviral infection: towards a structural understanding of the APOBEC proteins. Virology (2005) 1.36
Retrovirus RNA trafficking: from chromatin to invasive genomes. Traffic (2006) 1.30
Evidence for IFNα-induced, SAMHD1-independent inhibitors of early HIV-1 infection. Retrovirology (2013) 1.16
The SOCS-box of HIV-1 Vif interacts with ElonginBC by induced-folding to recruit its Cul5-containing ubiquitin ligase complex. PLoS Pathog (2010) 1.15
Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure. J Virol (2010) 1.15
Target cell-mediated editing of HIV-1 cDNA by APOBEC3 proteins in human macrophages. J Virol (2011) 1.12
Matrix mediates the functional link between human immunodeficiency virus type 1 RNA nuclear export elements and the assembly competency of Gag in murine cells. J Virol (2009) 1.07
SnapShot: HIV-1 proteins. Cell (2008) 1.06
Hepatitis B virus DNA is subject to extensive editing by the human deaminase APOBEC3C. Hepatology (2007) 1.05
Endogenous MOV10 inhibits the retrotransposition of endogenous retroelements but not the replication of exogenous retroviruses. Retrovirology (2012) 1.00
SRp40 and SRp55 promote the translation of unspliced human immunodeficiency virus type 1 RNA. J Virol (2010) 0.98
HIV-1 replication and APOBEC3 antiviral activity are not regulated by P bodies. J Virol (2012) 0.94
Nuclear import of SAMHD1 is mediated by a classical karyopherin α/β1 dependent pathway and confers sensitivity to VpxMAC induced ubiquitination and proteasomal degradation. Retrovirology (2014) 0.90
AIDS/HIV. HIV interplay with SAMHD1. Science (2012) 0.89
Rationalisation of the differences between APOBEC3G structures from crystallography and NMR studies by molecular dynamics simulations. PLoS One (2010) 0.87
Evolution of a species-specific determinant within human CRM1 that regulates the post-transcriptional phases of HIV-1 replication. PLoS Pathog (2011) 0.86
The innate antiviral factor APOBEC3G targets replication of measles, mumps and respiratory syncytial viruses. J Gen Virol (2011) 0.85
Insight into the HIV-1 Vif SOCS-box-ElonginBC interaction. Open Biol (2013) 0.77
Corrigendum: Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events. Nat Immunol (2016) 0.75
A plea for justice for jailed medical workers. Science (2006) 0.75
Corrigendum: Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events. Nat Immunol (2016) 0.75